OncoGenex Pharmaceuticals (NASDAQ:OGXI) had its target price reduced by Stifel Nicolaus from $26.00 to $21.00 in a report issued on Friday, Analyst Ratings Network reports. They currently have a buy rating on the stock.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) traded down 1.83% on Friday, hitting $7.235. The stock had a trading volume of 33,767 shares. OncoGenex Pharmaceuticals has a 52 week low of $6.55 and a 52 week high of $13.75. The stock has a 50-day moving average of $8.11 and a 200-day moving average of $9.30. The company’s market cap is $106.2 million.
Separately, analysts at Needham & Company upgraded shares of OncoGenex Pharmaceuticals from a buy rating to a strong-buy rating in a research note to investors on Monday, October 28th. They now have a $30.00 price target on the stock, up previously from $20.00. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. OncoGenex Pharmaceuticals has a consensus rating of Buy and an average target price of $21.38.
OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.